04K Stock Overview
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.84 |
| 52 Week High | CA$4.12 |
| 52 Week Low | CA$3.40 |
| Beta | 0.17 |
| 1 Month Change | -0.52% |
| 3 Month Change | 4.92% |
| 1 Year Change | -4.48% |
| 3 Year Change | 0.52% |
| 5 Year Change | -24.71% |
| Change since IPO | 0.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 04K | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.7% | 2.2% | 2.5% |
| 1Y | -4.5% | -17.6% | 13.4% |
Return vs Industry: 04K exceeded the German Pharmaceuticals industry which returned -15.5% over the past year.
Return vs Market: 04K underperformed the German Market which returned 15% over the past year.
Price Volatility
| 04K volatility | |
|---|---|
| 04K Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 04K has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 04K's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 745 | Samira Sakhia | www.knighttx.com |
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.
Knight Therapeutics Inc. Fundamentals Summary
| 04K fundamental statistics | |
|---|---|
| Market cap | €386.36m |
| Earnings (TTM) | €2.77m |
| Revenue (TTM) | €237.04m |
139.9x
P/E Ratio1.6x
P/S RatioIs 04K overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 04K income statement (TTM) | |
|---|---|
| Revenue | CA$371.30m |
| Cost of Revenue | CA$196.90m |
| Gross Profit | CA$174.41m |
| Other Expenses | CA$170.07m |
| Earnings | CA$4.33m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 0.044 |
| Gross Margin | 46.97% |
| Net Profit Margin | 1.17% |
| Debt/Equity Ratio | 5.5% |
How did 04K perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 08:08 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Knight Therapeutics Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |
| Tania Armstrong-Whitworth | Canaccord Genuity |